Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have improved the survival
of several cancers. However, they may cause a wide range of immune-related adverse …

Background A systematic review and meta-analysis was performed to estimate mortality in
adult patients with solid or hematological malignancies and SARS-CoV-2 infection. Methods …

Background Racial and social disparities exist in outcomes related to cancer and
cardiovascular disease (CVD). Objectives The aim of this cross-sectional study was to study …

Background Cardiovascular disease (CVD), one of the most common comorbidities of
coronavirus disease 2019 (COVID-19), has been suspected to be associated with adverse …

COVID‐19 has infected 272 million patients and caused 5.33 million deaths around the
world, and it remains the main global threat. Previous studies revealed that Chinese …

Background: Since the beginning of the SARS-CoV-2 pandemic, cancer patients affected by
COVID-19 have been reported to experience poor prognosis; however, a detailed …

Background The reported incidence of venous thromboembolism (VTE) in COVID-19
patients varies widely depending on patient populations sampled and has been …

Purpose of review Contemporary anticancer immunotherapy, particularly immune
checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell therapy, has changed …

Abstract HSPA5 (BiP, GRP78) has been reported as a potential host-cell receptor for SARS-
Cov-2, but its expression profiles on different tissues including tumors, its susceptibility to …

Opinion statement Prostate cancer is the second leading cause of cancer death in men, and
cardiovascular disease is the number one cause of death in patients with prostate cancer …